Screener
Pacira BioSciences, Inc. PCRX Business Segments — Income Tax
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Changes in the fair value of contingent consideration | (2,277) | (2,675) |
| Legal settlement | — | 7,000 |
| Other (2) | 880 | 1,862 |
| Total operating expenses | 170,474 | 166,933 |
| Total other (expense) income, net | (1,904) | 6,716 |
| Income before income taxes | 4,998 | 8,706 |
| Income tax expense | (2,082) | (3,894) |
| Net income | $2,916 | $4,812 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Pacira BioSciences, Inc.'s business segments — income tax?
- Pacira BioSciences, Inc. (PCRX) reported business segments — income tax of $2.08M in Q1 2026.
- How has Pacira BioSciences, Inc.'s business segments — income tax changed year-over-year?
- Pacira BioSciences, Inc.'s business segments — income tax decreased by 46.5% year-over-year, from $3.89M to $2.08M.
- What does business segments — income tax mean?
- This metric represents the total provision for income taxes allocated to the reportable segment based on its pre-tax earnings. It reflects the tax burden associated with the segment's operations in its respective jurisdictions. Analyzing this helps in understanding the effective tax rate and the impact of tax regulations on segment profitability.
Ask your AI about Pacira BioSciences, Inc.'s business segments — income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude